Why is Glenmark Pharma falling/rising?

As of 19-Aug, Glenmark Pharmaceuticals Ltd. is experiencing a decline in its stock price, currently at Rs 1,945.90, which reflects a decrease of Rs 28.5 or 1.44%. The stock has underperformed its sector by 1.31% today and has been on a downward trend for the last two days, accumulating a total decline of 4.56%. Despite the stock's strong performance over the long term, with a 20.95% increase year-to-date and a remarkable 402.62% rise over the last three years, it has faced challenges recently, including a 12.47% drop over the past month. The stock is currently trading above its 50-day, 100-day, and 200-day moving averages but below its 5-day and 20-day moving averages. Additionally, there has been a significant increase in investor participation, with delivery volume rising by 183.48% against the 5-day average, indicating heightened interest despite the price decline.
In the broader market context, Glenmark's recent performance contrasts sharply with the benchmark Sensex, which has gained 1.76% over the past week and is down only 0.14% over the past month. This disparity highlights the stock's struggles relative to the overall market. However, the company maintains a strong ability to service its debt, evidenced by a low Debt to EBITDA ratio of 1.00 times, and it benefits from high institutional holdings at 38.3%, which suggests confidence from more sophisticated investors. Furthermore, Glenmark has consistently outperformed the BSE500 over the last three years, which may provide some reassurance to investors despite the recent price decline.